Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
Eric Haaksma, Head of Animal Health Global Innovation at Boehringer Ingelheim says "At Boehringer Ingelheim, our dedication lies in translating scientific progress into cutting-edge innovations for animals and their owners. The launch of SENVELGO® underlines this ambition, offering a product that significantly enhances diabetic cat care and simplifies the lives of both cat owners and their feline companions."
Please click on this link (https://www.boehringer-ingelheim.com/animal-health/companion-animals/pets/cat-feline-diabetes-medication-treatment-eu-approval) for 'Notes to Editors' and 'References'.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
INGELHEIM, Germany -- Businesswire -- Boehringer Ingelheim, a global leader in animal health, has received marketing authorization from the European Commission for SENVELGO® (active ingredient: velagliflozin), marking a significant step for the treatment of feline diabetes in Europe. Globally, SENVELGO® is the first once-daily liquid oral solution for the reduction of hyperglycemia in cats with non-insulin-dependent diabetes mellitus. This breakthrough innovation will make it easier for cat owners to fit the treatment of feline diabetes into their daily lives.
Pet owners can give the once daily oral liquid solution with a small amount of food or directly into the cat’s mouth. As soon as one week after beginning treatment, SENVELGO® improves the clinical signs of diabetes that cats experience by reducing elevated blood glucose levels and minimizing the risk of clinical hypoglycemic events. The novel drug comes in liquid form, the formulation that cats and cat owners prefer, according to studies.
Dr. Stijn Niessen, President of the European College of Veterinary Internal Medicine (ECVIM), says, “SENVELGO® will revolutionize the management of feline diabetes in Europe in a way that improves the well-being of both cats and their owners. It eases the complexity and burden of feline diabetes treatment because of the apparent lack of danger for clinical hypoglycemia and removes the need for ongoing serial glucose monitoring. In this way, SENVELGO® will help the majority of owners to efficiently control their cat’s condition, significantly improving quality of life.”
Feline diabetes mellitus is a metabolic disorder which occurs when a cat has insufficient levels of, or an abnormal response to insulin. It is one of the most common endocrine disorders in cats, and this is expected to increase due to an increasing and growing cat population. Unfortunately, nearly one out of three cats who are diagnosed with diabetes are euthanized within the first year of diagnosis, with the complexity required to treat diabetic cats often being a contributing factor.
Eric Haaksma, Head of Animal Health Global Innovation at Boehringer Ingelheim says “At Boehringer Ingelheim, our dedication lies in translating scientific progress into cutting-edge innovations for animals and their owners. The launch of SENVELGO® underlines this ambition, offering a product that significantly enhances diabetic cat care and simplifies the lives of both cat owners and their feline companions.”
Following the marketing authorization in the European Union, SENVELGO® will be rolled out across EU countries. SENVELGO® is already approved in Switzerland, Great Britain, and the US. The company also plans to launch SENVELGO® in countries around the world, pending regulatory approvals.
Please click on this link (https://www.boehringer-ingelheim.com/animal-health/companion-animals/pets/cat-feline-diabetes-medication-treatment-eu-approval) for ‘Notes to Editors’ and ‘References’.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231122681664/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Boehringer Ingelheim
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 현대차-테이트 미술관, 파트너십 아홉 번째 전시 ‘현대 커미션: 이미래: Open Wound’ 개막 - 뉴스
- 큐리아, 밀라노 CPHI WW에서 새로 개편한 브랜드 아이덴티티 공개 - 뉴스와이어
- 현대자동차그룹, 신에너지부터 혁신제조까지 싱가포르와 공동연구한다 - 뉴스와이어
- GS25, 공식 파트너 넷플릭스와 손잡고 ‘흑백요리사: 요리 계급 전쟁’ 상품화 나서 - 뉴스와이어
- 삼성전자, 동남아 ‘비스포크 AI 콤보’ 테크세미나 개최 - 뉴스와이어
- JAIMA: 태국에서 ‘환경 오염 관리 심포지엄’ 개최 - 뉴스와이어
- 대만 디자인 엑스포, 타이난의 고유한 요리, 패션, 소프트 파워 역량 과시 - 뉴스와이어
- EU 인증 기관(BSI 네덜란드) 및 EMA, 유럽연합 및 유럽경제지역에서 EU 및 EEA에서 반플라타® 요법을
- 아바니아, 스페인의 메드텍 CRO 애너그램 인수로 새로운 유럽 지역에서 핵심 CRO 서비스 제공 강화
- 대한전선, 싱가포르 MEO와 해상풍력 사업 확장을 위한 MOU 체결 - 뉴스와이어